An Overview of Regular Dialysis Treatment in Japan as of 31 December 2003

:  A statistical survey of 3750 nationwide dialysis facilities was carried out by the Japanese Society for Dialysis Therapy (JSDT) at the end of 2003, with answers to the questionnaires received from 3717 facilities (99.12%). The population of dialysis patients in Japan at the end of 2003 was 237,71...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Therapeutic apheresis and dialysis 2005-12, Vol.9 (6), p.431-458
Hauptverfasser: Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan, Patient Registration Committee, Japanese Society for Dialysis Therapy
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 458
container_issue 6
container_start_page 431
container_title Therapeutic apheresis and dialysis
container_volume 9
creator Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
Patient Registration Committee, Japanese Society for Dialysis Therapy
description :  A statistical survey of 3750 nationwide dialysis facilities was carried out by the Japanese Society for Dialysis Therapy (JSDT) at the end of 2003, with answers to the questionnaires received from 3717 facilities (99.12%). The population of dialysis patients in Japan at the end of 2003 was 237,710, and the number of dialysis patients per million people was 1862.7. The crude death rate during a 1‐year period from the end of 2002 to the end of 2003 was 9.3%. The mean age of patients newly introduced to dialysis was 65.4 years, and the mean age of the entire dialysis population was 62.3 years. The primary diseases in the patients newly introduced to dialysis in 2003 included diabetic nephropathy (41.0% of patients) and chronic glomerulonephritis (29.1% of patients). The mean serum neutral fat concentration for all the dialysis patients was 113.9 ± 71.7 mg/dL (± SD). The mean serum low density lipoprotein (LDL)‐cholesterol concentration was 90.8 ± 30.9 mg/dL. Dialysate calcium concentrations ranging from 3.0 mEq/L to less than 3.5 mEq/L were used for majority of the dialysis patients (55.4%). Among anticoagulants given to the dialysis patients, heparins were the most commonly used in 79.3% of the dialysis patients. The relationship between blood pressure during dialysis and life expectancy for 1 year was analyzed for 43 465 patients who had undergone dialysis three times per week at the end of 2001. Results showed a significantly high mortality risk for patients who had systolic blood pressure of less than 100 mm Hg at the start of dialysis, systolic blood pressure of less than 100 mm Hg at the end of dialysis, and the greatest decrease (lowest) in systolic blood pressure of less than 120 mm Hg during dialysis. Patients who received vasopressor therapy during dialysis had a higher mortality risk than those who received no vasopressor therapy.
doi_str_mv 10.1111/j.1744-9987.2005.00328.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68899380</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68899380</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4948-b42a29df2f077cb78436bee9dd298d552ba7f3a8452fe77dcb3628dda82ced053</originalsourceid><addsrcrecordid>eNqNkMtOwzAQRS0Eorx-AXnFLsGxndiW2LQUSlEFqCpiaTnxBKUkabH7_HsSWpUts5mRfO6MdRDCEQmjpm6nYSQ4D5SSIqSExCEhjMpwc4TODg_Hh1moDjr3fkoIpZyxU9SJEhZzKpIzNOzW-HUFblXAGs9yPIbPZWkc7hem3PrC44kDs6igXuCixs9mbmpsfEuyCPchgyoFh5s_sEt0kpvSw9W-X6D3x4fJ_VMweh0M77ujIOOKyyDl1FBlc5oTIbJUSM6SFEBZS5W0cUxTI3JmJI9pDkLYLGUJldYaSTOwJGYX6Ga3d-5m30vwC10VPoOyNDXMll4nUirFJGlAuQMzN_PeQa7nrqiM2-qI6FajnurWkG5t6Vaj_tWoN030en9jmVZg_4J7bw1wtwPWRQnbfy_Wk-5bMzTxYBcv_AI2h7hxXzoRTMT642Wge6PxC3sjY91jP7ygjho</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68899380</pqid></control><display><type>article</type><title>An Overview of Regular Dialysis Treatment in Japan as of 31 December 2003</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan ; Patient Registration Committee, Japanese Society for Dialysis Therapy</creator><creatorcontrib>Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan ; Patient Registration Committee, Japanese Society for Dialysis Therapy</creatorcontrib><description>:  A statistical survey of 3750 nationwide dialysis facilities was carried out by the Japanese Society for Dialysis Therapy (JSDT) at the end of 2003, with answers to the questionnaires received from 3717 facilities (99.12%). The population of dialysis patients in Japan at the end of 2003 was 237,710, and the number of dialysis patients per million people was 1862.7. The crude death rate during a 1‐year period from the end of 2002 to the end of 2003 was 9.3%. The mean age of patients newly introduced to dialysis was 65.4 years, and the mean age of the entire dialysis population was 62.3 years. The primary diseases in the patients newly introduced to dialysis in 2003 included diabetic nephropathy (41.0% of patients) and chronic glomerulonephritis (29.1% of patients). The mean serum neutral fat concentration for all the dialysis patients was 113.9 ± 71.7 mg/dL (± SD). The mean serum low density lipoprotein (LDL)‐cholesterol concentration was 90.8 ± 30.9 mg/dL. Dialysate calcium concentrations ranging from 3.0 mEq/L to less than 3.5 mEq/L were used for majority of the dialysis patients (55.4%). Among anticoagulants given to the dialysis patients, heparins were the most commonly used in 79.3% of the dialysis patients. The relationship between blood pressure during dialysis and life expectancy for 1 year was analyzed for 43 465 patients who had undergone dialysis three times per week at the end of 2001. Results showed a significantly high mortality risk for patients who had systolic blood pressure of less than 100 mm Hg at the start of dialysis, systolic blood pressure of less than 100 mm Hg at the end of dialysis, and the greatest decrease (lowest) in systolic blood pressure of less than 120 mm Hg during dialysis. Patients who received vasopressor therapy during dialysis had a higher mortality risk than those who received no vasopressor therapy.</description><identifier>ISSN: 1744-9979</identifier><identifier>EISSN: 1744-9987</identifier><identifier>DOI: 10.1111/j.1744-9987.2005.00328.x</identifier><identifier>PMID: 16354276</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Science Pty</publisher><subject>Adolescent ; Adult ; Aged ; Anticoagulants - administration &amp; dosage ; Blood pressure ; Blood Pressure - physiology ; Child ; Child, Preschool ; Dialysis ; Female ; Health Care Surveys ; Heparin - administration &amp; dosage ; Humans ; Infant ; Infant, Newborn ; Japan - epidemiology ; Kidney Diseases - epidemiology ; Kidney Diseases - therapy ; Life Expectancy ; Lipids - blood ; Male ; Middle Aged ; Mortality ; Renal Dialysis - methods ; Renal Dialysis - utilization ; Risk Factors ; Survey ; Surveys and Questionnaires ; Survival Analysis ; Survival Rate ; Vasoconstrictor Agents - administration &amp; dosage ; Vasopressor</subject><ispartof>Therapeutic apheresis and dialysis, 2005-12, Vol.9 (6), p.431-458</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4948-b42a29df2f077cb78436bee9dd298d552ba7f3a8452fe77dcb3628dda82ced053</citedby><cites>FETCH-LOGICAL-c4948-b42a29df2f077cb78436bee9dd298d552ba7f3a8452fe77dcb3628dda82ced053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1744-9987.2005.00328.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1744-9987.2005.00328.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27922,27923,45572,45573</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16354276$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan</creatorcontrib><creatorcontrib>Patient Registration Committee, Japanese Society for Dialysis Therapy</creatorcontrib><title>An Overview of Regular Dialysis Treatment in Japan as of 31 December 2003</title><title>Therapeutic apheresis and dialysis</title><addtitle>Ther Apher Dial</addtitle><description>:  A statistical survey of 3750 nationwide dialysis facilities was carried out by the Japanese Society for Dialysis Therapy (JSDT) at the end of 2003, with answers to the questionnaires received from 3717 facilities (99.12%). The population of dialysis patients in Japan at the end of 2003 was 237,710, and the number of dialysis patients per million people was 1862.7. The crude death rate during a 1‐year period from the end of 2002 to the end of 2003 was 9.3%. The mean age of patients newly introduced to dialysis was 65.4 years, and the mean age of the entire dialysis population was 62.3 years. The primary diseases in the patients newly introduced to dialysis in 2003 included diabetic nephropathy (41.0% of patients) and chronic glomerulonephritis (29.1% of patients). The mean serum neutral fat concentration for all the dialysis patients was 113.9 ± 71.7 mg/dL (± SD). The mean serum low density lipoprotein (LDL)‐cholesterol concentration was 90.8 ± 30.9 mg/dL. Dialysate calcium concentrations ranging from 3.0 mEq/L to less than 3.5 mEq/L were used for majority of the dialysis patients (55.4%). Among anticoagulants given to the dialysis patients, heparins were the most commonly used in 79.3% of the dialysis patients. The relationship between blood pressure during dialysis and life expectancy for 1 year was analyzed for 43 465 patients who had undergone dialysis three times per week at the end of 2001. Results showed a significantly high mortality risk for patients who had systolic blood pressure of less than 100 mm Hg at the start of dialysis, systolic blood pressure of less than 100 mm Hg at the end of dialysis, and the greatest decrease (lowest) in systolic blood pressure of less than 120 mm Hg during dialysis. Patients who received vasopressor therapy during dialysis had a higher mortality risk than those who received no vasopressor therapy.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anticoagulants - administration &amp; dosage</subject><subject>Blood pressure</subject><subject>Blood Pressure - physiology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Dialysis</subject><subject>Female</subject><subject>Health Care Surveys</subject><subject>Heparin - administration &amp; dosage</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Japan - epidemiology</subject><subject>Kidney Diseases - epidemiology</subject><subject>Kidney Diseases - therapy</subject><subject>Life Expectancy</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Renal Dialysis - methods</subject><subject>Renal Dialysis - utilization</subject><subject>Risk Factors</subject><subject>Survey</subject><subject>Surveys and Questionnaires</subject><subject>Survival Analysis</subject><subject>Survival Rate</subject><subject>Vasoconstrictor Agents - administration &amp; dosage</subject><subject>Vasopressor</subject><issn>1744-9979</issn><issn>1744-9987</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtOwzAQRS0Eorx-AXnFLsGxndiW2LQUSlEFqCpiaTnxBKUkabH7_HsSWpUts5mRfO6MdRDCEQmjpm6nYSQ4D5SSIqSExCEhjMpwc4TODg_Hh1moDjr3fkoIpZyxU9SJEhZzKpIzNOzW-HUFblXAGs9yPIbPZWkc7hem3PrC44kDs6igXuCixs9mbmpsfEuyCPchgyoFh5s_sEt0kpvSw9W-X6D3x4fJ_VMweh0M77ujIOOKyyDl1FBlc5oTIbJUSM6SFEBZS5W0cUxTI3JmJI9pDkLYLGUJldYaSTOwJGYX6Ga3d-5m30vwC10VPoOyNDXMll4nUirFJGlAuQMzN_PeQa7nrqiM2-qI6FajnurWkG5t6Vaj_tWoN030en9jmVZg_4J7bw1wtwPWRQnbfy_Wk-5bMzTxYBcv_AI2h7hxXzoRTMT642Wge6PxC3sjY91jP7ygjho</recordid><startdate>200512</startdate><enddate>200512</enddate><creator>Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan</creator><creator>Patient Registration Committee, Japanese Society for Dialysis Therapy</creator><general>Blackwell Science Pty</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200512</creationdate><title>An Overview of Regular Dialysis Treatment in Japan as of 31 December 2003</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4948-b42a29df2f077cb78436bee9dd298d552ba7f3a8452fe77dcb3628dda82ced053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anticoagulants - administration &amp; dosage</topic><topic>Blood pressure</topic><topic>Blood Pressure - physiology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Dialysis</topic><topic>Female</topic><topic>Health Care Surveys</topic><topic>Heparin - administration &amp; dosage</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Japan - epidemiology</topic><topic>Kidney Diseases - epidemiology</topic><topic>Kidney Diseases - therapy</topic><topic>Life Expectancy</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Renal Dialysis - methods</topic><topic>Renal Dialysis - utilization</topic><topic>Risk Factors</topic><topic>Survey</topic><topic>Surveys and Questionnaires</topic><topic>Survival Analysis</topic><topic>Survival Rate</topic><topic>Vasoconstrictor Agents - administration &amp; dosage</topic><topic>Vasopressor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan</creatorcontrib><creatorcontrib>Patient Registration Committee, Japanese Society for Dialysis Therapy</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Therapeutic apheresis and dialysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><aucorp>Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan</aucorp><aucorp>Patient Registration Committee, Japanese Society for Dialysis Therapy</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An Overview of Regular Dialysis Treatment in Japan as of 31 December 2003</atitle><jtitle>Therapeutic apheresis and dialysis</jtitle><addtitle>Ther Apher Dial</addtitle><date>2005-12</date><risdate>2005</risdate><volume>9</volume><issue>6</issue><spage>431</spage><epage>458</epage><pages>431-458</pages><issn>1744-9979</issn><eissn>1744-9987</eissn><abstract>:  A statistical survey of 3750 nationwide dialysis facilities was carried out by the Japanese Society for Dialysis Therapy (JSDT) at the end of 2003, with answers to the questionnaires received from 3717 facilities (99.12%). The population of dialysis patients in Japan at the end of 2003 was 237,710, and the number of dialysis patients per million people was 1862.7. The crude death rate during a 1‐year period from the end of 2002 to the end of 2003 was 9.3%. The mean age of patients newly introduced to dialysis was 65.4 years, and the mean age of the entire dialysis population was 62.3 years. The primary diseases in the patients newly introduced to dialysis in 2003 included diabetic nephropathy (41.0% of patients) and chronic glomerulonephritis (29.1% of patients). The mean serum neutral fat concentration for all the dialysis patients was 113.9 ± 71.7 mg/dL (± SD). The mean serum low density lipoprotein (LDL)‐cholesterol concentration was 90.8 ± 30.9 mg/dL. Dialysate calcium concentrations ranging from 3.0 mEq/L to less than 3.5 mEq/L were used for majority of the dialysis patients (55.4%). Among anticoagulants given to the dialysis patients, heparins were the most commonly used in 79.3% of the dialysis patients. The relationship between blood pressure during dialysis and life expectancy for 1 year was analyzed for 43 465 patients who had undergone dialysis three times per week at the end of 2001. Results showed a significantly high mortality risk for patients who had systolic blood pressure of less than 100 mm Hg at the start of dialysis, systolic blood pressure of less than 100 mm Hg at the end of dialysis, and the greatest decrease (lowest) in systolic blood pressure of less than 120 mm Hg during dialysis. Patients who received vasopressor therapy during dialysis had a higher mortality risk than those who received no vasopressor therapy.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Science Pty</pub><pmid>16354276</pmid><doi>10.1111/j.1744-9987.2005.00328.x</doi><tpages>28</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1744-9979
ispartof Therapeutic apheresis and dialysis, 2005-12, Vol.9 (6), p.431-458
issn 1744-9979
1744-9987
language eng
recordid cdi_proquest_miscellaneous_68899380
source Wiley Online Library - AutoHoldings Journals; MEDLINE
subjects Adolescent
Adult
Aged
Anticoagulants - administration & dosage
Blood pressure
Blood Pressure - physiology
Child
Child, Preschool
Dialysis
Female
Health Care Surveys
Heparin - administration & dosage
Humans
Infant
Infant, Newborn
Japan - epidemiology
Kidney Diseases - epidemiology
Kidney Diseases - therapy
Life Expectancy
Lipids - blood
Male
Middle Aged
Mortality
Renal Dialysis - methods
Renal Dialysis - utilization
Risk Factors
Survey
Surveys and Questionnaires
Survival Analysis
Survival Rate
Vasoconstrictor Agents - administration & dosage
Vasopressor
title An Overview of Regular Dialysis Treatment in Japan as of 31 December 2003
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T09%3A16%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20Overview%20of%20Regular%20Dialysis%20Treatment%20in%20Japan%20as%20of%2031%20December%202003&rft.jtitle=Therapeutic%20apheresis%20and%20dialysis&rft.aucorp=Patient%20Registration%20Committee,%20Japanese%20Society%20for%20Dialysis%20Therapy,%20Tokyo,%20Japan&rft.date=2005-12&rft.volume=9&rft.issue=6&rft.spage=431&rft.epage=458&rft.pages=431-458&rft.issn=1744-9979&rft.eissn=1744-9987&rft_id=info:doi/10.1111/j.1744-9987.2005.00328.x&rft_dat=%3Cproquest_cross%3E68899380%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68899380&rft_id=info:pmid/16354276&rfr_iscdi=true